Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.59 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7474800 | 0.84 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTPDGFRBMAP4K4 | |
| SCHEMBL2798395 | 0.83 | HTT (0.61) | ALDH1A1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2794112 | 0.83 | KIT (0.59) | PDGFRBKITPDGFRAACHEBACE1 | |
| SCHEMBL30902259 | 0.83 | HTT (0.61) | ALDH1A1PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL16637216 | 0.82 | KIT (0.49) | ALDH1A1LMNAMAPTPDGFRBKIT | |
| SCHEMBL7481750 | 0.82 | MAPT (0.57) | ALDH1A1LMNAMAPTPDGFRBACHE | |
| SCHEMBL29765653 | 0.82 | KIT (0.49) | ALDH1A1LMNAMAPTPDGFRBKIT | |
| SCHEMBL2922036 | 0.82 | PDGFRB (0.59) | ALDH1A1LMNAMAPTPDGFRBKIT | |
| SCHEMBL12215173 | 0.80 | KIT (0.64) | LMNAPDGFRBKITMAP4K4 | |
| SCHEMBL6178429 | 0.80 | EIF2AK2 (0.64) | ALDH1A1LMNAPDGFRBACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| CN-1882347-A | AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | ALDH1A1 3849/4885LMNA 1430/4885MAPT 3331/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | ALDH1A1 3849/4885LMNA 1430/4885MAPT 3331/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | ALDH1A1 3849/4885LMNA 1430/4885MAPT 3331/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | ALDH1A1 3868/4885LMNA 1761/4885MAPT 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.